New drug combo takes on advanced cancers in first human trial

NCT ID NCT06868199

Recruiting now Disease control Sponsor: LaNova Medicines Limited Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new drug called LM-168, alone or with the immunotherapy toripalimab, in 87 adults with advanced solid tumours that have not responded to standard treatments. The study first checks safety and the right dose, then looks for signs that the tumours shrink. It is a first-in-human study, so the main goals are safety and tolerability, not yet a proven treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LM-168 (a new drug) and toripalimab (an immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumours that have not responded to standard therapies.
What could go wrong: This is a very early, first-in-human trial with only 87 participants. The drug may not be effective or could cause unexpected side effects. Success in this small study does not guarantee broader benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOURS

Contacts and locations

Locations

Bayview Health-Investigational Drug Services
RECRUITING

Perth, Western Australia, 6009, Australia
Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, China
Cancer Care Wollongong Pty Limited
RECRUITING

Wollongong, New South Wales, Australia
MUPharm Pty Limited trading as Macquarie University Hospital Parmarcy
RECRUITING

Ryde, New South Wales, 2109, Australia
Macquarie University
RECRUITING

Ryde, New South Wales, 2109, Australia
One Clinical Reasearch
RECRUITING

Perth, Western Australia, 6009, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.